Dr. Reddy’s Laboratories Ltd. announced the launch of Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration for treating Wilson’s disease.

Consumer advocacy group Public Citizen petitioned the FDA to pull Takeda’s gout treatment Uloric (febuxostat) off the market.

With the focus shifting away from the end reporting, companies have continued to invest in systems and processes that manage “upstream” relationships with healthcare providers and consultants, recognizing that the greater compliance risks center around these relationships than on the reported spend itself.

The U.S. FDA granted final approval to Aurobindo Pharma Limited’s generic treatment for multiple sclerosis.

Pfizer Inc. will invest $350 million to build a biotech center in China, the latest in a series of moves by pharma industry giants to set up shop in the world’s no. 2 drugs market.

Immunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.

Americans pay the highest prices in the world for cancer drugs, but the treatments are least affordable in lower income countries.

U.S. annual spending on prescription medicines will increase 22 percent over the next five years, climbing as high as $400 billion in 2020, according to a report released by IMS Health.

New service offers partner brands a no-risk approach to drive the marketing outcomes that matter most: new patient starts.

Lower-cost copies of complex biotech drugs, known as biosimilars, could save the United States and Europe’s five top markets as much as 98 billion euros ($110 bln) by 2020, a new analysis showed on Tuesday. Realizing those savings, however, depends on effective doctor education and healthcare providers adopting smart market access strategies, the report by […]